Buprenorphine treatment of opioid-dependent pregnant women: A comprehensive review

Addiction

Volumn 107, Issue SUPPL.1, 2012, Pages 5-27

  Jones, Hendrée E ^a,b   Heil, Sarah H ^c   Baewert, Andjela ^d   Arria, Amelia M ^e   Kaltenbach, Karol ^f   Martin, Peter R ^g   Coyle, Mara G ^h   Selby, Peter ⁱ   Stine, Susan M ^j   Fischer, Gabriele ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF MARYLAND   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h BROWN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Buprenorphine; Opioid dependence; Pharmacological treatment; Pregnancy

Indexed keywords

BUPRENORPHINE; METHADONE; MORPHINE; NARCOTIC ANTAGONIST;

ANALGESIA; BREAST MILK; CHEMISTRY; CHILD DEVELOPMENT; DRUG EFFECT; FEMALE; FETUS; HUMAN; LENGTH OF STAY; METHODOLOGY; NEWBORN; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBSTANCE ABUSE; TREATMENT OUTCOME; URINE; WITHDRAWAL SYNDROME;

BUPRENORPHINE; CHILD DEVELOPMENT; FEMALE; FETUS; HUMANS; INFANT, NEWBORN; LENGTH OF STAY; METHADONE; MILK, HUMAN; MORPHINE; NARCOTIC ANTAGONISTS; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PAIN MANAGEMENT; PATIENT DROPOUTS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME;

EID: 84868106768     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.04035.x     Document Type: Review

References (89)

1. Kaltenbach K., Berghella V., Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998; 25: 139-151.
2. Jones H. E., Tuten M., Keyser-Marcus L., Svikis D. Specialty treatment for women. In: Strain E. C., Stitzer M. L., editors. Methadone Treatment for Opioid Dependence. Baltimore: Johns Hopkins University Press; 2006, p. 455-484.
3. Unger A., Jung E., Winklbaur B., Fischer G. Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J Addict Dis 2010; 29: 217-230.
4. Winklbaur B., Kopf N., Ebner N., Jung E., Thau K., Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008; 103: 1429-1440.
5. Winklbaur B., Jung E., Fischer G. Opioid dependence and pregnancy. Curr Opin Psychiatry 2008; 21: 255-259.
6. Stoller K. B., Bigelow G. E., Walsh S. L., Strain E. C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 2001; 154: 230-242.
7. Jarvis M. A. E., Wu-Pong S., Kinseley J. S., Schnoll S. H. Alterations in methadone metabolism during late pregnancy. J Addict Dis 1999; 18: 51-61.
8. Cowan A., Lewis J. W., Macfarlane I. R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977; 60: 537-545.
9. Ariens E. J. Intrinsic activity: partial agonists and partial antagonists. J Cardiovasc Pharmacol 1983; 5: S8-15.
10. Walsh S. L., Preston K. L., Stitzer M. L., Cone E. J., Bigelow G. E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55: 569-580.
11. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication no. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
12. Johnson R. E., Chutuape M. A., Strain E. C., Walsh S. L., Stitzer M. L., Bigelow G. E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343: 1290-1297.
13. Kamien J. B., Branstetter S. A., Amass L. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid-dependent patients. Heroin Addict Relat Clin Probl 2008; 10: 5-18.
14. Bell J. R., Butler B., Lawrance A., Batey R., Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104: 73-77.
15. Auriacombe M., Franques P., Tignol J. Deaths attributable to methadone versus buprenorphine in France. JAMA 2001; 285: 45.
16. Dum J. E., Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 1981; 74: 627-633.
17. Kacinko S. L., Jones H. E., Johnson R. E., Choo R. E., Concheiro-Guisan M., Huestis M. A. Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment. Clin Chem 2009; 55: 1177-1187.
18. Jones H. E., Kaltenbach K., Heil S. H., Stine S. M., Coyle M. G., Arria A. M. etal. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-2331.
19. Jones H. E., Johnson R. E., Jasinski D. R., O'Grady K. E., Chisholm C. A., Choo R. E. etal. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79: 1-10.
20. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M. etal. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101: 275-281.
21. Albright B., de la Torre L., Skipper B., Price S., Abbott P., Rayburn W. Changes in methadone maintenance therapy during and after pregnancy. J Subst Abuse Treat 2011; 41: 347-353.
22. Huang P., Kehner G., Cowan A., Liu-Chen L.-Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001; 297: 688-695.
23. Concheiro M., Jones H., Johnson R. E., Shakleya D. M., Huestis M. A. Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 13-20.
24. Concheiro M., Jones H. E., Johnson R. E., Choo R., Shakleya D. M., Huestis M. A. Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes. Ther Drug Monit 2010; 32: 206-215.
25. Grimm D., Pauly E., Pöschl J., Linderkamp O., Skopp G. Buprenorphine and norbuprenorphine concentrations in human breast milk samples determined by liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2005; 27: 526-530.
26. Hytinantti T., Kahila H., Renlund M., Järvenpää A.-L., Halmesmäki E., Kivitie-Kallio S. Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Paediatr 2008; 97: 1040-1044.
27. Jones H. E., Fischer G., Heil S. H., Martin P. R., Kaltenbach K., Coyle M. G. etal. Maternal Opioid Treatment: Human Experimental Research (MOTHER)-approach, issues, and lessons learned. Addiction 2012; 107 (Suppl. 1): 28-35.
28. Jones H. E., Martin P. R., Heil S. H., Kaltenbach K., Selby P., Coyle M. G. etal. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008; 35: 245-259.
29. Rosado J., Walsh S. L., Bigelow G. E., Strain E. C. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend 2007; 90: 261-269.
30. Mattick R. P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; (2): CD002207.
31. Pond S. M., Kreek M. J., Tong T. G., Raghunath J., Benowitz N. L. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 1985; 233: 1-6.
32. Jones H. E., O'Grady K., Dahne J., Johnson R., Lemoine L., Milio L. etal. Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. Am J Drug Alcohol Abuse 2009; 35: 151-156.
33. Jones H. E., Johnson R. E., Milio L. Post-cesarean pain management of patients maintained on methadone or buprenorphine. Am J Addict 2006; 15: 258-259.
34. Höflich A. S., Langer M., Jagsch R., Böert A., Winklbaur B., Fischer G. etal. Peripartum pain management in opioid dependent women. Eur J Pain 2012; 16: 574-584.
35. Meyer M., Paranya G., Norris A. K., Howard D. Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy. Eur J Pain 2010; 14: 939-943.
36. Jansson L. M., DiPietro J. A., Velez M., Elko A., Williams E., Milio L. etal. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol 2011; 33: 240-243.
37. Salisbury A. L., Coyle M. G., O'Grady K. E., Martin P. R., Stine S. M., Kaltenbach K. etal. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction 2012; 107 (Suppl. 1): 36-44.
38. Lacroix I., Berrebi A., Chaumerliac C., Lapeyre-Mestre M., Montastruc J. L., Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction 2004; 99: 209-214.
39. Jernite M., Viville B., Escande B., Brettes J., Messer J. [Buprenorphine and pregnancy. Analysis of 24 cases]. Arch Pediatr 1999; 6: 1179-1185.
40. Colombini N., Elias R., Busuttil M., Dubuc M., Einaudi M.-A., Bues-Charbit M. Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone. Pharm World Sci 2008; 30: 227-234.
41. Lejeune C., Simmat-Durand L., Gourarier L., Aubisson S., Groupe d'Etudes Grossesse et Addictions (GEGA). Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82: 250-257.
42. Marquet P., Lavignasse P., Gaulier J., Lachatre G. Case study of neonates born to mothers undergoing buprenorphine maintenance treatment. In: Kintz P., Marquet P., editors. Buprenorphine Therapy of Opiate Addiction. Totowa, NJ: Humana Press; 2002, p. 123-135.
43. Kacinko S. L., Jones H. E., Johnson R. E., Choo R. E., Huestis M. A. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther 2008; 84: 604-612.
44. Lindemalm S., Nydert P., Svensson J.-O., Stahle L., Sarman I. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact 2009; 25: 199-205.
45. Marquet P., Chevrel J., Lavignasse P., Merle L., Lachâtre G. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther 1997; 62: 569-571.
46. Johnson R. E., Jones H. E., Jasinski D. R., Svikis D. S., Haug N. A., Jansson L. M. etal. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001; 63: 97-103.
47. Hirose M., Hosokawa T., Tanaka Y. Extradural buprenorphine suppresses breast feeding after caesarean section. Br J Anaesth 1997; 79: 120-121.
48. Academy of Breastfeeding Medicine Protocol Committee. ABM Clinical Protocol #21: Guidelines for Breastfeeding and the Drug-Dependent Woman. Breastfeed Med 2009; 4: 225-228.
49. Jones H. E., O'Grady K. E., Johnson R. E., Velez M., Jansson L. M. Infant neurobehavior following prenatal exposure to methadone or buprenorphine: results from the Neonatal Intensive Care Unit Network Neurobehavioral Scale. Subst Use Misuse 2010; 45: 2244-2257.
50. Coyle M. G., Salisbury A. S., Lester B. M., Jones H. E., Lin H., Graf-Rohrmesiter K., Fischer G. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction 2012; 107 (Suppl. 1): 63-73.
51. Schindler S. D., Eder H., Ortner R., Rohrmeister K., Langer M., Fischer G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 2003; 98: 103-110.
52. Kahila H., Kivitie-Kallio S., Halmesmäki E., Valanne L., Autti T. Brain magnetic resonance imaging of infants exposed prenatally to buprenorphine. Acta Radiol 2007; 48: 228-231.
53. Kayemba-Kay's S., Laclyde J. P. Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. Addiction 2003; 98: 1599-1604.
54. Whitham J. N., Spurrier N. J., Sawyer M. G., Baghurst P. A., Taplin J. E., White J. M. etal. The effects of prenatal exposure to buprenorphine or methadone on infant visual evoked potentials. Neurotoxicol Teratol 2010; 32: 280-288.
55. Sarfi M., Martinsen H., Bakstad B., Røislien J., Waal H. Patterns in sleep-wakefulness in three-month old infants exposed to methadone or buprenorphine. Early Hum Dev 2009; 85: 773-778.
56. Sarfi M., Smith L., Waal H., Sundet J. M. Risks and realities: dyadic interaction between 6-month-old infants and their mothers in opioid maintenance treatment. Infant Behav Dev 2011; 34: 578-589.
57. Salo S., Kivistö K., Korja R., Biringen Z., Tupola S.-M., Kivitie-Kallio S. Emotional availability, parental self-efficacy beliefs, and child development in caregiver-child relationships with buprenorphine-exposed 3-year-olds. Parent Sci Pract 2009; 9: 244-259.
58. Jones H. E., Kaltenbach K., O'Grady K. E. Methadone and the causes of maternal and perinatal complications: a response to Pinto etal., 'Substance abuse during pregnancy: effect on pregnancy outcomes' [Eur J Obstet Gynecol Reprod Biol, 2010. 150: 137-141]. Eur J Obstet Gynecol Reprod Biol 2011; 158: 116-117.
59. Jones H. E., Jansson L. M., Kaltenbach K. Methadone and perinatal outcomes: another perspective. Am J Obstet Gynecol 2011; 205: e11.
60. Winklbaur B., Baewert A., Jagsch R., Rohrmeister K., Metz V., Aeschbach Jachmann C. etal. Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res 2009; 15: 150-156.
61. Fischer G., Etzersdorfer P., Eder H., Jagsch R., Langer M., Weninger M. Buprenorphine maintenance in pregnant opiate addicts. Eur Addict Res 1998; 4: 32-36.
62. Ebner N., Rohrmeister K., Winklbaur B., Baewert A., Jagsch R., Peternell A. etal. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007; 87: 131-138.
63. Fischer G., Johnson R. E., Eder H., Jagsch R., Peternell A., Weninger M. etal. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000; 95: 239-244.
64. Rohrmeister K., Bernert G., Langer M., Fischer G., Weninger M., Pollak A. [Opiate addiction in gravidity-consequences for the newborn. Results of an interdisciplinary treatment concept]. Z Geburtshilfe Neonatol 2001; 205: 224-230.
65. Lejeune C., Aubisson S., Simmat-Durand L., Cneude F., Piquet M., Gourarier L., Groupe d'Etudes Grossesse et Addictions. [Withdrawal syndromes of newborns of pregnant drug abusers maintained under methadone or high-dose buprenorphine: 246 cases]. Ann Med Interne (Paris) 2001; 152: 21-27.
66. Lejeune C., Aubisson S., Simmat-Durand L., Cneude F., Piquet M. Buprenorphine and pregnancy: a comparative multi-center study of high-dose buprenorphine versus methadone maintenance. In: Kintz P., Marquet P., editors. Buprenorphine Therapy of Opiate Addiction. Totowa, NJ: Humana Press; 2002, p. 137-146.
67. Simmat-Durand L., Lejeune C., Gourarier L., Groupe d' Etudes Grossesse et Addictions (GEGA). Pregnancy under high-dose buprenorphine. Eur J Obstet Gynecol Reprod Biol 2009; 142: 119-123.
68. Vert P., Hamon I., Hubert C., Legagneur M., Hascoet J. M. [Infants of drug-addicted mothers: pitfalls of replacement therapy]. Bull Acad Natl Med 2008; 192: 961-969; discussion 969.
69. Lacroix I., Berrebi A., Garipuy D., Schmitt L., Hammou Y., Chaumerliac C. etal. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol 2011; 67: 1053-1059.
70. Lacroix I., Berrebi A., Schmitt L., Garripuy D., Laperyre-Mestre M., Montastruc J. L. etal. High buprenorphine dosage in pregnancy: first data of a prospective study. Drug Alcohol Depend 2002; 66: S97.
71. Kahila H., Saisto T., Kivitie-Kallio S., Haukkamaa M., Halmesmäki E. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand 2007; 86: 185-190.
72. Kahila H., Stefanovic V., Loukovaara M., Alfthan H., Hämäläinen E., Halmesmäki E. Prenatal buprenorphine exposure: effects on biochemical markers of hypoxia and early neonatal outcome. Acta Obstet Gynecol Scand 2008; 87: 1213-1219.
73. Kakko J., Heilig M., Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96: 69-78.
74. Binder T., Vavrinkova B. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett 2008; 29: 80-86.
75. Bakstad B., Sarfi M., Welle-Strand G. K., Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res 2009; 15: 128-134.
76. Blaser A., Pulzer F., Knüpfer M., Robel-Tillig E., Vogtmann C., Nickel P. etal. [Drug withdrawal in newborns-clinical data of 49 infants with intrauterine drug exposure: what should be done?] Klin Padiatr 2008; 220: 308-315.
77. Brulet C., Chanal C., Ravel P., Mazurier E., Boulot P., Faucherre V. [Multidisciplinary monitoring and psychosocial support reduce complications of opiate dependence in pregnant women: 114 pregnancies]. Presse Med 2007; 36: 1571-1580.
78. Sandtorv L., Reigstad H., Bruarøy S., Elgen I., Laegreid L. M. [Substitution treatment of drug addicts during pregnancy: consequences for the children?] Tidsskr Nor Laegeforen 2009; 129: 287-290.
79. Marquet P., Delpla P. A., Kerguelen S., Bremond J., Facy F., Garnier M. etal. Prevalence of drugs of abuse in urine of drivers involved in road accidents in France: a collaborative study. J Forensic Sci 1998; 43: 806-811.
80. Regini P., Cutrone M., Donzelli F., Flora P. G., Montesanto G. [Neonatal buprenorphine withdrawal syndrome, what is the right therapy?] Pediatr Med Chir 1998; 20: 67-69.
81. Herve F., Quenum S. [Buprenorphine (Subutex) and neonatal withdrawal syndrome]. Arch Pediatr 1998; 5: 206-207.
82. Auriacombe M., Afflelou S., Lavignasse P., Lafitte C., Roux D., Daulouède J. P. etal. [Pregnancy, abortion and delivery in a cohort of heroin dependent patients treated with drug substitution (methadone and buprenorphine) in Aquitaine]. Presse Med 1999; 28: 177.
83. Eder H., Rupp I., Peternell A., Fischer G. [Buprenorphine in pregnancy]. Psychiatr Prax 2001; 28: 267-269.
84. Siedentopf J., Nagel M., Eβer M., Casteleyn S., Dudenhausen J. W. Experience with buprenorphine induction and subsequent dose reduction as compared to treatment with L-methadone in pregnant opioid addicts. Geburtshilfe Frauenheilkd 2004; 64: 711-718.
85. Ross D. High dose buprenorphine in pregnancy. Aust NZ J Obstet Gynaecol 2004; 44: 80.
86. Unger A., Jagsch R., Jones H., Arria A., Leitich H., Rohrmeister K. etal. Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison. Addiction 2011; 106: 1355-1362.
87. Czerkes M., Blackstone J., Pulvino J. Buprenorphine versus Methadone Treatment for Opiate Addiction in Pregnancy: An Evaluation of Neonatal Outcomes. in The American College of Obstetricians and Gynecologists. San Francisco, CA. 2010. Available at: http://www.acog.org/acm/pdf/oralTue.pdf (originally accessed 8 January 2011. Now archived at: http://web.archive.org/web/20110101092028/http://www.acog.org/acm/pdf/oralTue.pdf). (Archived at http://www.webcitation.org/6ANWQebdv on 2 September 2012).
88. Blandthorn J., Forster D. A., Love V. Neonatal and maternal outcomes following maternal use of buprenorphine or methadone during pregnancy: findings of a retrospective audit. Women Birth 2011; 24: 32-39.
89. O'Connor A., Alto W., Musgrave K., Gibbons D., Llanto L., Holden S. etal. Observational study of buprenorphine treatment of opioid-dependent pregnant women in a family medicine residency: reports on maternal and infant outcomes. J Am Board Fam Med 2011; 24: 194-201.